SCHEMBL21536582

SCHEMBL21536582

CN(C(C)(C)c1ccc(CN2CC(=O)NC2=O)cc1)S(=O)(=O)c1cccc(OC2CCCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DUT P33316 7/20 0.49
▸ GRM2 Q14416 1/20 0.36
▸ KCNA5 P22460 1/20 0.35
▸ PSEN1 P49768 3/20 0.35
▸ PSEN2 P49810 3/20 0.35
▸ APH1B Q8WW43 3/20 0.35
▸ NCSTN Q92542 3/20 0.35
▸ APH1A Q96BI3 3/20 0.35
▸ PSENEN Q9NZ42 3/20 0.35
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ KAT6A Q92794 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189654 0.84 DUT (0.70) DUTGRM2DDB1CRBNKAT6A
SCHEMBL20189396 0.79 DUT (0.49) DUTGAAMEN1KMT2AKAT6A
SCHEMBL18379994 0.77 DUT (0.68) DUTGRM2DDB1CRBNGAA
SCHEMBL21536743 0.77 DUT (0.47) DUTGRM2DDB1CRBNKAT6A
SCHEMBL21536693 0.76 DUT (0.41) DUTDDB1CRBNMEN1KMT2A
SCHEMBL21536086 0.76 DUT (0.47) DUTGRM2DDB1CRBNKAT6A
SCHEMBL21536622 0.76 DUT (0.47) DUTGRM2DDB1CRBNKAT6A
SCHEMBL21536091 0.76 DUT (0.47) DUTGRM2DDB1CRBNKAT6A
SCHEMBL20201711 0.76 DUT (0.47) DUTGRM2GAAPDE4APDE4B
SCHEMBL21536744 0.76 DUT (0.47) DUTGRM2DDB1CRBNKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263773-A1 COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-08-24 — — US disclosed
US-20230263773-A1 COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-08-24 — — US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 — — US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263773-A1 COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS TYMP, DUT, TYMS DUT 2/4885GRM2 3962/4885KCNA5 4874/4885
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT DUT 3/4885GRM2 4457/4885KCNA5 3385/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT DUT 3/4885GRM2 4457/4885KCNA5 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback